Materialise (MTLS) Q3 2026 earnings review
Materialise grows medical and aerospace sales, but its profit falls
Materialise, a Belgian maker of 3D-printed medical implants and industrial parts, grew sales while its operating profit fell. Underlying revenue rose 5% from a year ago (2% as reported) because strong demand for medical devices and aerospace parts outweighed weak industrial software sales. However, chief executive Brigitte de Vet-Veithen stepped up research spending and headquarters costs rose, so operating profit excluding one-offs dropped 15%. Management kept its full-year outlook unchanged, which by our math requires growth to pick up to 5% in the fourth quarter.
| Sales excluding sold units | +4.9% reported revenue +2.1% (€67.7M) |
|---|---|
| Medical segment revenue | €36.5M +9.7% from a year ago |
| Operating profit, excluding one-offs | €2.5M -15% from a year ago (3.7% margin) |
| Full-year outlook | Unchanged middle of the range: €278M sales, €13M profit |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because the core medical unit stayed healthy and the full-year profit plan held firm despite higher third-quarter costs. Medical software sales rebounded to grow about 10% after shrinking last quarter, and cutting two unprofitable units brought the manufacturing division close to breakeven. The bad news: rising research expenses pulled the medical EBITDA margin down by 3 percentage points, breaking a four-quarter run of company-wide profit growth.
The question now is whether the medical division can keep funding heavier research spending without giving up its roughly 30% margin. Either the third-quarter margin dip was a temporary spike from unadjusted one-time costs, or heavier engineering spend is the new normal required to keep medical sales growing 10%. Fourth-quarter operating profit, which must reach €4.2 million to hit the middle of the full-year plan, will tell.
🐂 Bull Case
Medical Devices and Software Both Grew 10%
Materialise Medical makes custom 3D-printed surgical guides and implants, alongside planning software for doctors. It is the company's main profit engine and now brings in 54% of total revenue. Last quarter, medical software sales shrank 4% from a year ago because US universities faced funding cuts and hospitals delayed orthopedic purchases.
In the third quarter, total medical revenue rose 9.7% to €36.5 million. Finance chief Koen Berges said both medical devices and medical software grew around 10% from a year ago. Chief executive Brigitte de Vet-Veithen highlighted a new agreement in Ukraine to supply facial reconstruction plates and software training, plus new planning tools for heart valve and liver tumor surgeries.
This matters because the medical division carries the rest of the business. The rebound in software sales shows that hospital demand for digital surgical planning did not stall after the second-quarter dip.
What to watch: the exact split between medical software and device revenue in the full-year report. A second straight half of double-digit software growth would show that US hospital budgets have normalized.
Aerospace Demand Lifted Underlying Manufacturing Sales
Materialise Manufacturing prints industrial parts for customers, splitting its work between one-off prototypes and repeatable series production. Weak European industrial demand has kept the division in a deep operating loss, and reported sales fell 6.2% to €21.3 million after the company handed its RapidFit automotive tooling and Eyewear units to their management teams.
Excluding those sold units, underlying division revenue grew 1.5% from a year ago. By our math, the divested units generated about €1.7 million in the year-ago quarter. De Vet-Veithen noted "revenues for series production growing by more than 30% year-over-year in the quarter, driven by demand from the aerospace, semiconductor, and defense industries", so series work now roughly equals prototyping.
Cutting the unprofitable units and adding aerospace work narrowed the division's quarterly EBITDA loss (earnings before interest, taxes, depreciation and amortization, excluding one-offs) from €845 thousand to €257 thousand. Still, weak prototyping demand nearly wiped out the 30% gain in series production.
What to watch: fourth-quarter Manufacturing EBITDA. Moving above zero would fulfil management's commitment to make the division profitable on that measure for the full year.
🐻 Bear Case
Higher Research Spend Cut Medical Margins
For four straight quarters, Materialise grew operating profit faster than sales by holding operating expenses nearly flat. Management points to that cost discipline as the reason it raised its full-year profit outlook in August.
That streak ended this quarter. Operating profit excluding one-offs fell 14.8% from a year ago to €2.5 million, and the margin dropped 0.7 percentage points to 3.7% even though gross margin rose 0.9 points. The company spent more across every operating line, led by research and development and unallocated headquarters costs.
- Research and development: 18.9% of revenue, up 1.7 percentage points from a year ago
- General and administrative overhead: 15.5% of revenue, up 0.8 percentage points
- Sales and marketing: 23.0% of revenue, up 0.6 percentage points
- Medical segment EBITDA margin: 27.4%, down 3.2 percentage points from a year ago
Berges also blamed "some one-time costs in the quarter that we considered operational and therefore did not adjust for", while unallocated corporate headquarters expenses jumped €1.0 million. Because Medical is the only high-margin unit, a 3.2-point drop in its margin pulls down the whole group.
What to watch: fourth-quarter operating profit excluding one-offs, which must reach €4.2 million by our math to hit the middle of the full-year plan. Landing there would show the third-quarter cost spike was temporary.
Software Sales Kept Falling After the Subscription Shift
Materialise Software sells programs that prepare and manage 3D printing jobs, led by its cloud platform CO-AM. For two years, the company has shifted customers from one-time perpetual licences to yearly subscriptions, which depresses upfront revenue while building recurring sales.
In the third quarter, segment revenue fell 4.1% from a year ago to €9.9 million. Recurring revenue made up 84% of the total, down from 86% in the second quarter. Berges said the share has stabilized, "reaching the end of the transitioning from perpetual licenses to recurring license model".
With the billing transition finished, the revenue drop can no longer be blamed on accounting mechanics. De Vet-Veithen said selling CO-AM for factory series production takes much longer than selling traditional prototyping software because more customer teams must approve the deal.
What to watch: fourth-quarter Software revenue and software deferred revenue in the year-end report. The fourth quarter is the peak season for contract renewals, so another revenue drop would confirm that industrial customers are cutting seats.
👓 Other Themes
Government Grants and Lower Capex Lifted Net Cash
Net cash rose by €11.7 million over the first nine months to €82.5 million, even after Materialise spent €7.5 million buying back 2.4% of its shares. Nine-month free cash flow more than doubled to €22.8 million because capital spending fell by €6.2 million and the company collected €4.2 million in government grants for past investments. In July, management also drew the final €15 million of a credit facility, pushing gross debt to €71.1 million despite holding €153.5 million in cash.
💲 Other KPIs
Up 1.4% from a year ago by our math, slowing from 3.5% growth in the second quarter. Deferred revenue is cash customers have paid upfront for software licences, maintenance and projects not yet delivered. The software portion fell from €46.5 million in June to €45.0 million on normal third-quarter renewal timing.
Gross margin — the share of sales left after the direct cost of making products — rose 0.9 percentage points from 56.8% a year ago. That reverses a 1.5-point drop in the second quarter, helped by the exit of the lower-margin RapidFit and Eyewear units and a higher share of Medical revenue.
Weighted average diluted shares fell 1.7% from 59.1 million a year ago. Materialise resumed buying back shares on Nasdaq after its summer closed period ended, spending €2.3 million in the third quarter and €7.5 million across the first nine months.
🔮 Guidance
Unchanged. The plan calls for about 3.9% growth at the middle of the range, "fully absorbing the unfavorable revenue impact of the recent RapidFit and Eyewear divestitures". By our math, hitting the €278 million middle requires €74.0 million of revenue in the fourth quarter, or 5.4% growth from a year ago against 2.1% in the third quarter.
Unchanged. Management kept the target it raised from €10–12 million in August, pointing to 22.6% full-year growth at the €13 million middle of the range. By our math, that leaves €4.2 million for the fourth quarter (a 5.6% margin), up 4.6% from a strong year-ago quarter.
❓ Key Questions
What were the "one-time operational costs" left in Adjusted EBIT?
Finance chief Koen Berges said third-quarter profit was hurt by one-time operational costs that management chose not to strip out, while corporate headquarters costs rose €1.0 million. Knowing their size and nature shows whether the third-quarter margin drop will repeat.
How much revenue did RapidFit and Eyewear generate in 2025?
By our math, the two sold units generated about €1.7 million in the third quarter of 2025. Management still has not given the fourth-quarter 2025 baseline, which investors need to judge the underlying growth implied by the full-year outlook.
Why draw €15 million of new debt while holding €154 million in cash?
Materialise drew the final €15 million tranche of its credit facility in July even though cash far exceeds total debt and nine-month capital spending was only €5.6 million. Management has not named any acquisition or large factory project requiring the cash.
When will longer CO-AM sales cycles turn into Software revenue growth?
With the shift to recurring licences now finished at 84% of Software revenue, management blamed the 4.1% revenue drop on longer approval times for its CO-AM factory software. Investors have no backlog or contract count to track those deals.